Amgen is no exception to this dynamic. Although 2017's Tax Cuts and Jobs Act spurred the company to build a handful of new ...

The robust performance of two major Hong Kong stock listings this week has raised hopes that a small group of elite Chinese ...

China will provide a more efficient, transparent and predictable regulatory environment to support technology firms listing ...

Peter Lu, at McDermott Will & Emery discusses China’s opening of its health industry to international investors ...

As technology continues to advance, the integration of AI into various aspects of the pharmaceutical industry will undeniably drive innovation, improve patient outcomes, and reshape the future of ...

President Donald Trump signed an executive order Monday that he said will slash drug prices by approximately 59% or more ...

3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

For the Trump administration, pharmaceuticals are as much a national security issue as they are an issue of health or ...

Wildlife conservation activists have welcomed an update to China’s list of officially sanctioned medicines, which drops 13 ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...